Schedule of Interim Consolidated Financial Information |
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal 2013 Quarter Ended |
|
|
|
March 31 |
|
June 30 |
|
September 30 |
|
December 31 |
|
Revenues(1) |
|
$ |
71,077 |
|
$ |
101,675 |
|
$ |
85,123 |
|
|
97,072 |
|
Net loss |
|
$ |
(15,669 |
) |
$ |
(2,571 |
) |
$ |
(22,037 |
) |
|
(42,870 |
) |
Basic and diluted net loss per share |
|
$ |
(0.12 |
) |
$ |
(0.02 |
) |
$ |
(0.14 |
) |
|
(0.26 |
) |
Shares used in computation of basic and diluted net loss per share |
|
|
134,345 |
|
|
142,284 |
|
|
155,067 |
|
|
161,914 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal 2012 Quarter Ended |
|
|
|
March 31 |
|
June 30 |
|
September 30 |
|
December 31 |
|
Revenues(2) |
|
$ |
36,179 |
|
$ |
86,542 |
|
$ |
60,492 |
|
$ |
113,845 |
|
Net income (loss) |
|
$ |
(45,426 |
) |
$ |
4,037 |
|
$ |
(21,710 |
) |
$ |
18,779 |
|
Basic net income (loss) per share |
|
$ |
(0.36 |
) |
$ |
0.03 |
|
$ |
(0.17 |
) |
$ |
0.14 |
|
Diluted net income (loss) per share |
|
$ |
(0.36 |
) |
$ |
0.03 |
|
$ |
(0.17 |
) |
$ |
0.14 |
|
Shares used in computation of basic net income (loss) per share |
|
|
127,203 |
|
|
129,224 |
|
|
130,851 |
|
|
131,711 |
|
Shares used in computation of diluted net income (loss) per share |
|
|
127,203 |
|
|
137,969 |
|
|
130,851 |
|
|
139,118 |
|
- (1)
- The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $48.3 million, $54.1 million, $60.2 million and $72.8 million, respectively of product revenues, net, relating to JAKAFI. The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $5.9 million, $5.8 million, $8.2 million and $8.4 million, respectively of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2013, June 30, 2013, September 30, 2013 and December 31, 2013 include $16.7 million, $41.7 million, $16.7 million and $15.8 million, respectively of contract revenues relating to these agreements.
- (2)
- The quarters ended March 31, 2012, June 30, 2012, September 30, 2012 and December 31, 2012 include $19.3 million, $29.7 million, $43.7 million and $43.3 million, respectively of product revenues, net, relating to JAKAFI. The quarter ended December 31, 2012 includes $3.7 million of product royalty revenues related to the sale of JAKAVI outside the United States. In November 2009 and December 2009, we entered into collaborative research and license agreements with Novartis and Lilly, respectively. The quarters ended March 31, 2012, June 30, 2012, September 30, 2012 and December 31, 2012 include $16.7 million, $56.7 million, $16.7 million and $66.7 million, respectively of contract revenues relating to these agreements.
|